New research reveals that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Published data in a prominent health publication demonstrates that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users using such treatments should be aware of the potential of rapid rebound weight gain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight within about 18 months.
Analyzing Approaches
The study, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through dieting usually see a less rapid weight regain—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Doctors propose the mode of action of the jabs is key to understanding the amplified regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making overeating far more likely."
A Lifelong Issue?
Health authorities suggest the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals contend that, considering the likelihood of weight regain, the treatment might need to be life-long.
This perspective is reinforced by pharmaceutical companies, who say that the results "underscore the chronic nature of excess weight," similar to managing diseases like diabetes.
User Testimonies
Users who have discontinued the medication describe a intense return of appetite.
"It felt as if a switch activating and I was suddenly extremely hungry," recalled an individual.
This challenge is compounded if patients have not developed permanent dietary or behavioural modifications during therapy.
Growing Use
Recent estimates suggest that a significant number of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is higher among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and lasting health benefits relies on ongoing behavioural management.
